Market View

U.S. Market
The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq regained their respective 50-DMA this
week and are now testing resistance at October highs (S&P 500: 3,550; Nasdaq: 11,965). The 10- and 21-

DMA have begun to turn back up and will now act as near-term resistance should a pullback occur. The distri-
bution day count stands at seven and five, respectively, with one day expiring on each Monday.

Market View

U.S. Market
The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq broke below their respective 50-
DMA this week and are now testing support near September lows, followed by the rising 200-DMA (S&P 500:
3,129; Nasdaq: 9,833). We will likely downgrade the market to Downtrend for the first time since the April
2 follow-through day should either index close below September lows (S&P 500: 3,209; Nasdaq: 10,519).
Should that occur, we will be looking for another follow-through day before advising an increase in risk.

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq held above their respective 50-
DMA (S&P 500: 3,408; Nasdaq: 11,305) following a low volume pullback to that level this week. That moving
average remains near-term support, while resistance remains 3,550 on the S&P 500 and 11,965 on the
Nasdaq. The distribution day count stands at six and three, respectively, with one day expiring on each next
week.

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. Indices are consolidating strong gains off their respective 50-
DMA. Support is at the rising 10-DMA (S&P 500: 3,459; Nasdaq: 11,580). The distribution day count is seven
and four on the S&P 500 and the Nasdaq, respectively, with two days expiring on each index next week.

NeoGenomics

Key points from this report:

 

  • Buy NeoGenomics (NEO). The stock is actionable as it builds the right side of a 10-week cup with a pivot of $41.03.
  • Oncology testing recovery. NeoGenomics is expected to report triple-digit earnings growth in 2021, driven by a rapid and strong recovery in core oncology testing volume. COVID-19 testing should result in an incremental revenue and earnings opportunity.
  • Liquid biopsy opportunity. Liquid biopsy remains another strong growth engine for the company. On June 29, NeoGenomics launched three liquid biopsy tests with a turnaround time of just seven days or less.
  • Margin expansion. Driven by a 30%+ test volume CAGR, NeoGenomics has reduced its cost per test 41% since 2011. Consequently, its gross margin expanded to 48.1% in 2019 from 44.7% in 2011.
  • Pharma business. The restarting of clinical trials and patient enrollment with no significant cancellation will improve the outlook for their pharma services business. Management expects the pharma service business to grow 20%+ over the long term.